Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Deuterated compound and application thereof in treatment of cancer

A compound and hydrate technology, applied in the field of deuterated compounds and their application in the treatment of cancer, can solve problems such as explaining or explaining the chemical properties and biological activities of deuterium-enriched axitinib

Pending Publication Date: 2021-03-05
RISEN SUZHOU PHARMA TECH CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, US2009062347 only broadly describes various deuterated axitinib without further explaining or illustrating the chemical properties and biological activities of any deuterium-enriched axitinib

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Deuterated compound and application thereof in treatment of cancer
  • Deuterated compound and application thereof in treatment of cancer
  • Deuterated compound and application thereof in treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0129] Example 1: N-(trideuteromethyl)-2-((3-((1E)-2-(2-pyridyl)vinyl)-1H-indazol-6-yl)thio)benzene Formamide (compound A) preparation

[0130] Aqueous NaOH solution (NaOH, 83.2 g, 2.08 mmol, 5.0 eq.; water, 132 mL) was placed in the reaction flask and cooled to 0 °C. At 0°C, first add CD to the reaction flask 3 OD (15g, 0.416mol, 1.0eq.), then a solution of TsCl in THF (TsCl, 95g, 0.500mol, 1.2eq.; THF, 132mL) was slowly added dropwise. After the dropwise addition, the temperature of the system was raised to room temperature, and the reaction mixture was continuously stirred at room temperature for 16 h. Then acetic acid (94.5 g) was added dropwise at 25° C. to neutralize, and filtered. The filtrate was extracted twice with ethyl acetate (200 mL each), the filter cake was dissolved in water (200 mL), and extracted twice with ethyl acetate (200 mL each), and the organic phases were combined. The organic phase was saturated with Na 2 CO 3 solution (300mL) after washing, w...

Embodiment 2

[0136] Example 2: N-(trideuteromethyl)-2-((3-((1E)-2-(2-pyridyl)vinyl)-1-(2,5,8,11-tetraoxo Preparation of heterododecanoyl)-1H-indazol-6-yl)thio)benzamide (compound 5)

[0137] Add triethylene glycol monomethyl ether (500mg, 3.045mmol, 1.0eq.), tetrahydrofuran (10mL) and triethylamine (616mg, 6.09mmol, 2.0eq.) successively in the reaction flask, and place the mixture in an ice-water bath Cool down to 0°C. Then, a tetrahydrofuran solution of phenyl p-nitrochloroformate (675 mg dissolved in 10 mL tetrahydrofuran, 3.350 mmol, 1.1 eq.) was added dropwise into the reaction system. Warm up to room temperature and stir for 5 hours. The reaction was monitored by TLC until the starting material was consumed. Concentrate to remove most of the solvent, then add more water (40 mL) and ethyl acetate (40 mL). The layers were separated by extraction and washing, and the organic phase was separated. The organic phase was concentrated, and the residue was separated and purified by silica...

Embodiment 3

[0139] Example 3: N-(trideuteromethyl)-2-((3-((1E)-2-(2-pyridyl)vinyl)-1-((1-naphthyloxy)((1S )-(1-methoxycarbonylethyl)amino)phosphinoyl)-1H-indazol-6-yl)thio)benzamide (compound 10)

[0140] Naphthol (720 mg, 4.99 mmol, 1.0 eq.) and diethyl ether (20 mL) were added to a reaction vial. Under the protection of nitrogen, the reaction system was placed under the cooling condition of -78 ° C, and phosphorus oxychloride (765 mg, 4.99 mmol, 1.0 eq.) and triethylamine (504 mg, 4.99 mmol, 1.0 eq.) were added dropwise to the above solution. ). The reaction mixture was stirred at -78°C for 1 hour, then slowly warmed to room temperature and stirred overnight. The insoluble matter was removed by filtration, and the filtrate was concentrated to obtain (1-naphthyloxy)phosphoryl dichloride (1.2 g, 92%). 1 H NMR (500MHz, CDCl 3 ): δppm 7.47(t, J=8.0Hz, 1H), 7.53-7.68(m, 3H), 7.82(d, J=8.0Hz, 1H), 7.91(d, J=7.7Hz, 1H), 8.10( d, J=7.9Hz, 1H).

[0141] Add (1-naphthyloxy)phosphoryl dichlo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a deuterated compound and application thereof in the treatment of cancer. Specifically, the present invention provides the compound of formula (I) and pharmaceuticallyacceptable salt or ester thereof, and a pharmaceutical composition thereof. The compound and the pharmaceutical composition are used for inhibiting or regulating the activity of tyrosine kinase and treating disease symptoms or symptoms including cancer mediated by tyrosine kinase.

Description

technical field [0001] The present invention relates to N-(trideuteromethyl)-2-((3-((1E)-2-(2-pyridyl)vinyl)-1H-indazole-6 which are tyrosine kinase inhibitors -yl)thio)benzamide and derivatives thereof, and their use for inhibiting or regulating the activity of tyrosine kinases or treating disease symptoms or conditions mediated by tyrosine kinases, such as cancer. Background technique [0002] Axitinib (chemical name: N-methyl-2-((3-((1E)-2-(2-pyridyl)vinyl)-1H-indazol-6-yl)thio)benzyl Amide; trade name: ) is a small molecule tyrosine kinase inhibitor (TKI) useful in the treatment of cancer (see eg WO2001002369, the structure of which is shown below). It has been shown that axitinib can significantly inhibit the growth of breast cancer in animal xenograft models (Wilmes, L.J. et al., Magn. Reson. Imaging, 2007, 25(3):319-327). The drug has shown partial response in clinical trials of renal cell carcinoma (RCC) (Rini, B. et al., J. of Clin. Oncol. 2005, ASCO Annual Meet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D401/06C07F9/6558C07F9/6574C07D401/14A61K31/4439A61K31/675A61P35/00
CPCC07D401/06C07F9/65583C07F9/65744C07D401/14C07F9/65586A61P35/00A61K31/4439A61K31/675C07F9/6558C07F9/6574Y02P20/55
Inventor 吕佳声顾家敏张启国陈刚孔宪起
Owner RISEN SUZHOU PHARMA TECH CO LTD
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More